Stability of Rapidly Crystallizing Sulfonamides Glasses by Fast Scanning Calorimetry: Crystallization Kinetics and Glass-Forming Ability

Production and evaluation of the kinetic stability of the amorphous forms of active pharmaceutical ingredients are among the current challenges of modern pharmaceutical science. In the present work, amorphous forms of several sulfonamides were produced for the first time using Fast Scanning calorimetry. The parameters, characterizing the glass-forming ability of the compounds, i.e. the critical cooling rate of the melt and the kinetic fragility, were determined. The cold crystallization kinetics was studied using both isothermal and non-isothermal approaches. The results of the present study will contribute to the development of approaches for producing amorphous forms of rapidly crystallizing active pharmaceutical ingredients.

The Relevance of Crystal Forms in the Pharmaceutical Field: Sword of Damocles or Innovation Tools?

This review is aimed to provide to an “educated but non-expert” readership and an overview of the scientific, commercial, and ethical importance of investigating the crystalline forms (polymorphs, hydrates, and co-crystals) of active pharmaceutical ingredients (API). The existence of multiple crystal forms of an API is relevant not only for the selection of the best solid material to carry through the various stages of drug development, including the choice of dosage and of excipients suitable for drug development and marketing, but also in terms of intellectual property protection and/or extension. This is because the physico-chemical properties, such as solubility, dissolution rate, thermal stability, processability, etc., of the solid API may depend, sometimes dramatically, on the crystal form, with important implications on the drug’s ultimate efficacy. This review will recount how the scientific community and the pharmaceutical industry learned from the catastrophic consequences of the appearance of new, more stable, and unsuspected crystal forms. The relevant aspects of hydrates, the most common pharmaceutical solid solvates, and of co-crystals, the association of two or more solid components in the same crystalline materials, will also be discussed. Examples will be provided of how to tackle multiple crystal forms with screening protocols and theoretical approaches, and ultimately how to turn into discovery and innovation the purposed preparation of new crystalline forms of an API.

Steps towards a nature inspired inorganic crystal engineering

This Perspective outlines the results obtained at the University of Bologna by applying crystal engineering strategies to develop nature inspired organic-inorganic materials to tackle challenges in the health and environment sectors. It is shown by means of a number of examples that co-crystallization of inorganic salts, such as alkali and transition metal halides, with organic compounds, such as amino acids, urea, thiourea and quaternary ammonium salts, can be successfully used for (i) chiral resolution and conglomerate formation from racemic compounds, (ii) inhibition of soil enzyme activity in order to reduce urea decomposition and environmental pollution, and (iii) preparation of novel agents to tackle antimicrobial resistance. All materials described in this Perspective have been obtained by mechanochemical solvent-free or slurry methods and characterized by solid state techniques. The fundamental idea is that a crystal engineering approach based on the choice of intermolecular interactions (coordination and hydrogen bonds) between organic and inorganic compounds allows obtaining materials with collective properties that are different, and often very much superior to those of the separate components. It is also demonstrated that the success of this strategy depends crucially on cross-disciplinary synergistic exchange with expert scientists in the areas of bioinorganics, microbiology, and chirality application-oriented developments of these novel materials.

Profoundly improved photostability of dimetronidazole by cocrystallization

Cocrystallization with saccharine (SAC) significantly improved photostability of dimetronidazole (DMZ), an veterinary antibiotic.

Recent Advance of Melt Crystallization, Towards Process Intensification and Techniques Development

Melt crystallization has been considered as a green separation technique and widely applied in industry and manufacture due to several attractive features, including no need for solvent, achieving specific product...

Recent Progress of Antisolvent Crystallization

Antisolvent crystallization is a significant unit operation in the pharmaceutical industry, especially on drug crystal properties optimization. This paper firstly highlights the applications of antisolvent crystallization in crystal engineering. Antisolvent...

Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications

Pharmaceutical cocrystals are multicomponent systems in which at least one component is an active pharmaceutical ingredient and the others are pharmaceutically acceptable ingredients. Cocrystallization of a drug substance with a coformer is a promising and emerging approach to improve the performance of pharmaceuticals, such as solubility, dissolution profile, pharmacokinetics and stability. This review article presents a comprehensive overview of pharmaceutical cocrystals, including preparation methods, physicochemical properties, and applications. Furthermore, some examples of drug cocrystals are highlighted to illustrate the effect of crystal structures on the various aspects of active pharmaceutical ingredients, such as physical stability, chemical stability, mechanical properties, optical properties, bioavailability, sustained release and therapeutic effect. This review will provide guidance for more efficient design and manufacture of pharmaceutical cocrystals with desired physicochemical properties and applications.

Modification of hygroscopicity and tabletability of l-carnitine by a cocrystallization technique

LC-MYR cocrystal with significant enhanced dissolution,tabletability and decreased hygroscopicity is more suitable for manufacturing solid dosage forms.

Composing Novel Diclofenac Potassium and l-Proline Salt Cocrystal as a Strategy to Increase Solubility and Dissolution

This research dealt with the multicomponent crystal developed from diclofenac potassium and l-proline to improve the pharmaceutical performance of this anti-inflammatory drug. Slow evaporation of the component mixture at a 1:1 M ratio, supported by ultrasonication, yielded a new salt cocrystal, which was characterized using thermal analysis, Karl Fischer titration, infrared spectrophotometry, powder diffractometry, and single crystal diffractometry. This salt cocrystal was confirmed as a tetrahydrate that comprised diclofenac potassium, l-proline, and water (1:1:4), named DKPH. The new salt cocrystal enhanced the solubility of diclofenac potassium by up to 3.56 folds and accelerated the intrinsic dissolution rate of 3.36 folds. It was supported by the solid and solution phase intermolecular interaction study. A different phase, which indicated a monohydrate form of the salt cocrystal, was found from the low humidity chamber during the isotherm sorption study. However, the tetrahydrate, DKPH, was proven as a stable form under ambient conditions.

Solution chemistry and phase solubility diagrams of CL-20/MTNP energetic cocrystals

The solubility behavior and solution chemistry of CL-20/MTNP (2,4,6,8,10,12-hexanitro-hexaaza-isowurtzitane/1-methyl-3,4,5-trinitropyrazole) energetic cocrystals in organic solvents were first investigated to offer some important information on thermodynamics.

Cocrystal construction between the ethyl ester with parent drug of diclofenac: structural, stability, and anti-inflammatory study

This study aimed to collect the crystallographic data of ethyl diclofenac and discover a cocrystal from this ester with its parent, diclofenac acid, and to investigate their physicochemical properties and anti-inflammation activity. Firstly, ethyl diclofenac single crystal was isolated and continued by the cocrystal screening and isolation. Solid characterization was conducted by thermal analysis, infrared spectroscopy, powder x-ray diffractometry, followed by structural determination using a single crystal x-ray diffractometer. The stability of the cocrystal toward heating and high humidity, followed by the anti-inflammatory activity, was also studied. Ethyl diclofenac and the cocrystal were successfully isolated and subsequently subjected to lattice system determination. Interestingly, the new cocrystal can be generated directly by Fischer equilibrium reaction during esterification of diclofenac acid. Structurally, ethyl diclofenac reveals a P21/c monoclinic and the cocrystal between this ester with its parent drug is a P-1 triclinic system. A hydrophobic interaction -C-Cl-, which is rarely found in a cocrystal, involved in the molecular interaction between ethyl diclofenac and the parent drug, besides the hydrogen bonds. The newly isolated cocrystal has a melting point ±103–104 °C, which is higher than that of ethyl diclofenac (±67.5 °C) but lower than that of diclofenac acid (±173 °C). Hence, this cocrystal is stable towards accelerated stability testing by heating in a microwave, as well as storing in high relative humidity. Moreover, the anti-inflammation test also showed promising activity improvement.

Melatonin loaded with bacterial cellulose nanofiber by Pickering-emulsion solvent evaporation for enhanced dissolution and bioavailability

The objective of the present work aimed to explore the potential of bacterial cellulose (BC) for oral delivery of melatonin (MLT), a natural hormone that faces problems of low solubility and oral bioavailability. BC was hydrolyzed by sulfuric acid followed by the oxidation to prepare bacterial cellulose nanofiber suspension (BCNs). Melatonin-loaded bacterial cellulose nanofiber suspension (MLT-BCNs) was prepared by emulsion solvent evaporation method. The properties of freeze-dried BCs and MLT-BCNs were studied by Fluorescence microscopy (FM), scanning electron microscopy (SEM), Fourier-transform infrared (FTIR), X-ray diffraction (XRD), differential scanning calorimetry (DSC) and thermo gravimetric (TG). The results indicated that the fibers in BCNs became short and thin compared with BC, MLT in MLT-BCNs was uniformly distributed, both BCNs and MLT-BCNs have good thermodynamic stability. The MLT-BCNs showed more rapid dissolution MLT rates compared to the commercially available MLT in SGF and SIF, the dissolution of the cumulative release rate was about 2.1 times of the commercially available MLT. The oral bioavailability of MLT-BCNs in rat was about 2.4 times higher than the commercially available MLT. Thus, MLT-BCNs could act as promising delivery with enhanced dissolution and bioavailability for MLT after oral administration.

Mechanochemical preparation of molecular and ionic co-crystals of the hormone melatonin

Molecular and ionic co-crystals of melatonin with piperazine, DABCO and CaCl₂ were obtained via kneading with ethanol: the solubility of melatonin in H₂O increases by an order of magnitude when combined with CaCl₂.

Melatonin May Increase Anticancer Potential of Pleiotropic Drugs

Melatonin (N-acetyl-5-methoxytryptamine) is not only a pineal hormone, but also an ubiquitary molecule present in plants and part of our diet. Numerous preclinical and some clinical reports pointed to its multiple beneficial effects including oncostatic properties, and as such, it has become one of the most aspiring goals in cancer prevention/therapy. A link between cancer and inflammation and/or metabolic disorders has been well established and the therapy of these conditions with so-called pleiotropic drugs, which include non-steroidal anti-inflammatory drugs, statins and peroral antidiabetics, modulates a cancer risk too. Adjuvant therapy with melatonin may improve the oncostatic potential of these drugs. Results from preclinical studies are limited though support this hypothesis, which, however, remains to be verified by further research.

Engineering Cocrystals of PoorlyWater-Soluble Drugs to Enhance Dissolution in Aqueous Medium

Biopharmaceutics Classification System (BCS) Class II and IV drugs suffer from poor aqueous solubility and hence low bioavailability. Most of these drugs are hydrophobic and cannot be developed into a pharmaceutical formulation due to their poor aqueous solubility. One of the ways to enhance the aqueous solubility of poorlywater-soluble drugs is to use the principles of crystal engineering to formulate cocrystals of these molecules with water-soluble molecules (which are generally called coformers). Many researchers have shown that the cocrystals significantly enhance the aqueous solubility of poorly water-soluble drugs. In this review, we present a consolidated account of reports available in the literature related to the cocrystallization of poorly water-soluble drugs. The current practice to formulate new drug cocrystals with enhanced solubility involves a lot of empiricism. Therefore, in this work, attempts have been made to understand a general framework involved in successful (and unsuccessful) cocrystallization events which can yield different solid forms such as cocrystals, cocrystal polymorphs, cocrystal hydrates/solvates, salts, coamorphous solids, eutectics and solid solutions. The rationale behind screening suitable coformers for cocrystallization has been explained based on the rules of five i.e., hydrogen bonding, halogen bonding (and in general non-covalent bonding), length of carbon chain, molecular recognition points and coformer aqueous solubility. Different techniques to screen coformers for effective cocrystallization and methods to synthesize cocrystals have been discussed. Recent advances in technologies for continuous and solvent-free production of cocrystals have also been discussed. Furthermore, mechanisms involved in solubilization of these solid forms and the parameters influencing dissolution and stability of specific solid forms have been discussed. Overall, this review provides a consolidated account of the rationale for design of cocrystals, past efforts, recent developments and future perspectives for cocrystallization research which will be extremely useful for researchers working in pharmaceutical formulation development.

Pharmaceutical cocrystallization techniques. Advances and challenges

Cocrystals are homogenous (single-phase) crystalline structures composed by two or more components in a definite stoichiometric ratio bonded together by noncovalent bonds. Pharmaceutical industry has been showing interest in cocrystals due to their ability to improve active pharmaceutical ingredients (API's) properties, such as solubility, dissolution, bioavailability, stability and processability. The necessity for high-throughput screening methods and methods capable of producing cocrystals in an industrial scale still hinders the use of cocrystals by the pharmaceutical industry. The aim of this review is to present an extensive overview of the cocrystallization methods, focusing in the specificities of each technique, its advantages and disadvantages. The review is divided into solvent-based and solvent-free methods. The most appropriate methods to the different stages of cocrystals manufacture, from the screening phase to industrial production are identified. The use of continuous and scalable methods in cocrystal production as well as the implementation of quality-by-design and process analytical technology concepts are also addressed.

Recent advances in improving oral drug bioavailability by cocrystals

Introduction: Oral drug delivery is the most favored route of drug administration. However, poor oral bioavailability is one of the leading reasons for insufficient clinical efficacy. Improving oral absorption of drugs with low water solubility and/or low intestinal membrane permeability is an active field of research. Cocrystallization of drugs with appropriate coformers is a promising approach for enhancing oral bioavailability.

Methods: In the present review, we have focused on recent advances that have been made in improving oral absorption through cocrystallization. The covered areas include supersaturation and its importance on oral absorption of cocrystals, permeability of cocrystals through membranes, drug-coformer pharmacokinetic (PK) interactions, conducting in vivo-in vitro correlations for cocrystals. Additionally, a discussion has been made on the integration of nanocrystal technology with supramolecular design. Marketed cocrystal products and PK studies in human subjects are also reported.

Results: Considering supersaturation and consequent precipitation properties is necessary when evaluating dissolution and bioavailability of cocrystals. Appropriate excipients should be included to control precipitation kinetics and to capture solubility advantage of cocrystals. Beside to solubility, cocrystals may modify membrane permeability of drugs. Therefore, cocrystals can find applications in improving oral bioavailability of poorly permeable drugs. It has been shown that cocrystals may interrupt cellular integrity of cellular monolayers which can raise toxicity concerns. Some of coformers may interact with intestinal absorption of drugs through changing intestinal blood flow, metabolism and inhibiting efflux pumps. Therefore, caution should be taken into account when conducting bioavailability studies. Nanosized cocrystals have shown a high potential towards improving absorption of poorly soluble drugs.

Conclusions: Cocrystals have found their way from the proof-of-principle stage to the clinic. Up to now, at least two cocrystal products have gained approval from regulatory bodies. However, there are remaining challenges on safety, predicting in vivo behavior and revealing real potential of cocrystals in the human.

Pharmaceutical cocrystallization: an effective approach to modulate the physicochemical properties of solid-state drugs

This highlight presents an update on applications of cocrystallization to modify properties relevant to efficacy, safety, and manufacturability of drugs.

Suppressed hydration in metoclopramide hydrochloride by salt cocrystallisation

Salt cocrystallisation method successfully suppressed hydration and lowered the dissolution rate of the pharmaceutical salt crystals.

Melatonin-loaded silica coated with hydroxypropyl methylcellulose phthalate for enhanced oral bioavailability: Preparation, and in vitro-in vivo evaluation

Melatonin (MLT) is a small molecule with low water solubility and high permeability. According to the Biopharmaceutics Classification System, MLT is a class II drug exhibiting a very short half-life and minimal and variable bioavailability. This work aimed to establish a delivery system composed of an enteric MLT nanosphere with favorably controlled and sustained release characteristics superior to those of raw MLT. The nanosphere was composed of hydroxypropyl methylcellulose phthalate (HP55) and silica (SiO₂) with MLT. As a carrier, SiO₂ contains numerous surface pores with high adsorption capacity advantageous for permeability and slow release. HP55 is a good enteric coating material. MLT-loaded SiO₂ was obtained through adsorption in acetone solution. A MLT-loaded SiO₂ coated with HP55 (MLT-SiO₂-HP55) nanosphere was prepared via desolvation. The characteristics of this nanosphere were analyzed through transmission electron microscopy, Brunauer-Emmett-Teller surface area analysis, diffuse reflectance infrared Fourier transform spectroscopy, X-ray diffraction, differential scanning calorimetry, and thermogravimetric analysis. Results show that MLT was loaded mostly in the pores of SiO₂. HP55 was coated on a large portion of MLT-SiO₂. In vitro release studies revealed that the release rate of MLT from MLT-SiO₂ was higher than that of raw MLT in simulated gastric fluid (SGF). The amount of MLT released from MLT-SiO₂-HP55 in SGF was lower than that released from simulated intestinal fluid because of HP55 coated on MLT-SiO₂. In vivo evaluation demonstrated the controlled drug release of MLT-SiO₂-HP55 in rats. Compared with raw MLT, MLT-SiO₂-HP55 prolonged peak time (T_max) from 15min to 30min and increased peak concentration (C_max) from 168.86ng/mL to 383.71ng/mL. The corresponding area under the curve (AUC) of MLT-SiO₂-HP55 was 3.5 times higher than that of raw MLT. This finding illustrated the sustained release of MLT-SiO₂-HP55. Our in vitro release and in vivo absorption studies indicated that the proposed preparation of MLT-SiO₂-HP55 is an effective method to facilitate the controlled and sustained release of MLT with enhanced bioavailability.

Cocrystals of the antiandrogenic drug bicalutamide: screening, crystal structures, formation thermodynamics and lattice energies

Two new cocrystals of the antiandrogenic drug bicalutamide with benzamide and salicylamide are reported. Relationships between crystal structures, melting temperatures, aqueous dissolution, formation thermodynamics and crystal lattice energies of the cocrystals are investigated.

Physicochemical and mechanical properties of paracetamol cocrystal with 5-nitroisophthalic acid

We report novel pharmaceutical cocrystal of a popular antipyretic drug paracetamol (PCA) with coformer 5-nitroisophhthalic acid (5NIP) to improve its tabletability. The cocrystal (PCA-5NIP at molar ratio of 1:1) was synthesized by solvent evaporation technique using methanol as solvent. The physicochemical properties of cocrystal were characterized by powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), thermogravimetry analysis (TGA), fourier transform infrared spectroscopy (FTIR), hot stage polarized microscopy (HSPM) and scanning electron microscopy (SEM). Stability of the cocrystal was assessed by storing them at 40°C/75% RH for one month. Compared to PCA, the cocrystal displayed superior tableting performance. PCA-5NIP cocrystal showed a similar dissolution profile as compared to PCA and exhibited good stability. This study showed the utility of PCA-5NIP cocrystal for improving mechanical properties of PCA.